Kurzbeschreibung
(Englisch)
|
Fighting diseases of poverty: Drugs for Neglected Diseases Initiative (DNDi)
Neglected tropical diseases, affecting poor and marginalised populations in low- and middle-income countries, urgently need the development of new, life-saving, and affordable medicines. The Geneva-based Drugs for Neglected Diseases initiative leads these efforts and provides access to innovative treatments. This work is in line with Swiss values of collaboration and innovation, and contributes to equitable access to quality medicines.
| Pays/région |
Thème |
Période |
Budget |
Monde entier
|
Santé
Maladies infectieuses
Renforcement des systèmes de santé
|
01.01.2025 - 31.12.2028
|
CHF7’200’000
|
| Contexte |
Neglected tropical diseases (NTDs) are a group ofinfectious diseases that are prevalent in tropical andsubtropical regions and affect over one billion peopleannually. Treatments and diagnostics are oftenineffective, costly, or unavailable. Left untreated,neglected tropical diseases severely impact health,wellbeing, and socio-economic participation, and stillcause 200,000 deaths each year.
The Drugs for Neglected Diseases initiative (DNDi) is aGeneva-based not-for-profit research organisationdeveloping new, life-saving and affordable treatments forneglected patients, strengthening research capacity inlow-income countries, and advocating for innovation andaccess. DNDi fosters collaborations among key actors incountries affected by these diseases, including healthministries, national disease control programmes,medicine regulatory authorities, WHO, academia, andcivil society groups, as well as clinicians and healthprofessionals. These partnerships enable DNDi todevelop treatments that meet the specific needs ofaffected communities and to deliver the treatments thatpatients need.
Switzerland plays a leading role in the global fightagainst neglected tropical diseases. Swiss researchinstitutions, pharmaceutical companies, internationalnon-governmental organisations, and internationalcooperation are at the forefront of this effort. The SDChas been supporting DNDi’s work since 2005. Swissactors such as research institutions (Swiss Tropical andPublic Health Institute) and pharmaceutical companies(including Roche, Novartis) are key partners of DNDi.DNDi complements the mandate of other global healthactors based in Geneva and is an asset to "GenèveInternationale".
|
| Objectifs |
Ensure equitable access totherapeutic products forneglected tropical diseases.
The specific objective is todeliver 5 to 8 new treatmentsbetween 2025 and 2028.
|
| Groupes cibles |
Direct beneficiaries:One billion people worldwideaffected by neglected tropicaldiseases, mainly in Africa andmostly those living in remoterural areas, urban slums orconflict zones.
Other beneficiaries:Local clinicians, scientists, andexperts in low- and middleincomecountries.
|
| Effets à moyen terme |
Outcome 1:New treatmentsadapted to the needs ofvulnerable populations aredeveloped, registered, andused.
Outcome 2:Knowledge, dataand expertise are shared withstakeholders working onneglected diseases in endemiccountries.
Outcome 3: Policy makers aremobilised and accountable toenable and sustain equitableand inclusive R&D ecosystemsfor priority public health.
|
| Résultats |
Principaux résultats attendus:
- 5 to 8 new treatments are delivered between 2025-28.
- Health system actors, including communities, areengaged to provide treatment and diagnostics.
- Researchers, patients, communities, and authoritiesin countries collaborate in active, equitablepartnerships that drive the drug developmentprocess.
- International and national R&D norms and policiesare in place for open, transparent, and equitablepartnerships for drug development.
Principaux résultats antérieurs:
Since its inception in 2003, DNDi has developed 13treatments for six deadly diseases, saving millions oflives. Recent key achievements include:
- Development of fexinidazole, the first oral treatmentfor sleeping sickness, in 2018. This revolutionarytreatment was registered in 2022 for a rarer but moresevere form of the disease.
- Development of a new and highly effective drug,ravidasvir, for hepatitis C and its registration inMalaysia, China, and Egypt by 2022.
- Development of child-friendly HIV antiretroviralformulations in 2019 and registration in South Africa,Kenya, Mali, Mozambique, and Uganda by 2023.
- DNDi launched the Dengue Alliance with partners inendemic countries to identify effective drugs.
|
| Direction/office fédéral responsable |
DDC
|
| Partenaire de projet |
Partenaire contractuel
Institution universitaire et de recherche étrangère
- Drugs for Neglected Diseases initiative (DNDi)
|
| Coordination avec d'autres projets et acteurs |
World HealthOrganisation - ExpandedSpecial Project for Eliminationof Neglected Tropical Diseases- The Swiss Alliance againstNTDs (“NTD cluster”), WorldHealth Organisation, SpecialProgram for Research andTraining in Tropical Diseases,Medicines for Malaria Venture,Swiss Tropical and PublicHealth Institute, Swissmedic. |
| Budget |
Phase en coursBudget de la SuisseCHF7’200’000Budget suisse déjà attribuéCHF1’800’000Projet total depuis la première phaseBudget de la SuisseCHF28’900’000Budget y compris partenaires de projetCHF36’100’000 |
| Phases du projet |
Phase 5 01.01.2025 - 31.12.2028 (Phase en cours)Phase 4 01.01.2021 - 31.12.2024 (Completed)Phase 3 01.01.2017 - 31.12.2020 (Completed)Phase 2 01.01.2013 - 31.12.2016 (Completed) |
|
